Ultragenyx Pharmaceutical (RARE) Total Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Total Liabilities rose 31.39% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 31.39% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 29.33% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• Over the last five years, Total Liabilities for RARE reached as high as $1.6 billion in Q4 2025 and fell as low as $587.6 million in Q1 2022.
• Historically, Total Liabilities has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2023.
• Across the five-year window, Total Liabilities soared 108.6% in 2022 and decreased 3.21% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $1.2 billion in 2022, then climbed by 1.9% to $1.2 billion in 2023, then rose by 2.09% to $1.2 billion in 2024, then advanced by 29.33% to $1.6 billion in 2025, then fell by 4.98% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.2 billion in Q3 2025.